ASX Biotech Investing In 2026: Investors Are More Aware Of The Hard Lessons, But Have Forgotten The Hidden Rewards Of It

ASX Biotech Investing has always been the market’s most difficult arena. Yes tech and resources are risky spaces too, but at least a gold explorer can gain just off the back of gold price momentum or activity from neighbouring peers.

In the biotech space, it is all on the success of the individual company. The science is extraordinary and the ambition is genuine, but the path from hypothesis to commercial product remains brutally narrow. The potential rewards are real; the capacity for sudden ruin is just as real. Recent events on the ASX have delivered that message with unusual clarity, particularly through the experiences of Opthea and Immutep.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

ASX Biotech Investing Is At Its Worst When the Dream Dies in Phase 3

Opthea’s collapse was a year ago but still worth noting because one of the most instructive episodes in recent ASX history. For years, the company had been developing sozinibercept, a VEGF‑C/D inhibitor for wet AMD, a condition affecting millions across the US and Europe. Early Phase 2 data in 2019 was encouraging enough to attract substantial institutional capital, including more than US$283m in non‑dilutive funding through a Development Funding Agreement with Carlyle Group and an unnamed co‑investor, supplemented by further equity raises. The narrative was carefully constructed. Then 1H25 arrived.

The Phase 3 COAST trial, which tested whether sozinibercept combined with aflibercept outperformed aflibercept alone, failed its primary endpoint. Patients in the combination arm recorded a mean improvement of 13.5 letters versus 13.7 for monotherapy. Not an outright failure in the sense of not working at all, but no meaningful difference and no secondary endpoint advantages. When the company unblinded its second Phase 3 study, ShORe, the results were equally conclusive. Both trials were terminated.

The consequences were immediate and severe. Termination clauses in the DFA exposed Opthea to potential liabilities of up to US$680m. The company suspended trading, cut more than 80% of its workforce, removed half its board and entered negotiations that ultimately produced a settlement of US$20m in cash plus a near‑10% equity stake for the DFA investors. From a stock that had traded at 60 cents before suspension, shareholders were left with almost nothing.

Immutep Hit Home the Reality Too!

Turning to more recent events, Immutep’s experience was more recent but no less confronting. The company had spent years building the case for eftilagimod alfa (efti), a LAG‑3 fusion protein designed to stimulate immune responses against cancer. Phase 2 data across multiple indications, including NSCLC, head and neck cancer and breast cancer, was promising enough to secure a partnership with Merck and a regional licensing deal with Dr. Reddy’s Laboratories worth US$20m upfront and up to US$349.5m in milestones.

The pivotal Phase 3 study, TACTI‑004, evaluated efti combined with Keytruda in first‑line NSCLC. In March 2026, the independent data monitoring committee recommended termination for futility. The stock fell more than 88% in a single session. Analysts who had previously described the Phase 2 survival data as “impressive” were left reassessing the assumptions that had underpinned their optimism. It was a reminder that Phase 2 promise does not equate to Phase 3 proof, a distinction the market often forgets.

These failures do not indicate that the ASX biotech space has become uniquely dangerous. They simply reflect the reality of drug development. Industry‑wide, the probability of a drug progressing from Phase 1 to approval sits somewhere between 7% and 15%, depending on the therapeutic area. Phase 3 failure rates remain high, often cited at around 40–50%. The COAST and TACTI‑004 outcomes are painful, but they are not anomalies; they are representative of the statistical base rate.

What has changed is visibility. More retail investors now hold biotech stocks, market commentary is louder, and the emotional amplitude of the sector has increased. The “realisation” that biotech is difficult is not new information; it is simply arriving later for a broader audience.

But There Are Two Sides To the Ledger

Focusing solely on the casualties would misrepresent the sector. The same period that produced Opthea’s collapse and Immutep’s Phase 3 failure also delivered some of the most significant commercial successes in Australian biotech.

Telix Pharmaceuticals (ASX:TLX) is the standout. The company has built one of the strongest growth trajectories on the ASX. Its prostate cancer imaging agent Illuccix secured approvals from the FDA, Health Canada, the TGA and European regulators.

The company’s revenue in 2025 was US$804m (approximately $1.2bn), off the back of Illucix mostly, but a second imaging product, Gozellix, received FDA approval in March 2025 and launched commercially in the US. This is what success looks like when science, regulatory execution and commercial strategy align.

Neuren Pharmaceuticals (ASX:NEU) provides another example. Daybue, its treatment for Rett syndrome, launched in North America in April 2023 through partner Acadia Pharmaceuticals and had enrolled more than 1,300 patients by mid‑2024. The company continues to advance its pipeline across related neurological indications.

And amongst earlier-stage peers, Nyrada (ASX:NYR) has been one of the sector’s unexpected movers, rising more than 5,000% from early 2024 to late 2025 on the back of positive cardiac and neuroprotective data for its lead compound Xolatryp.

Are Devices and Diagnostics Safer?

Don’t forget the healthcare space is more than just drugs, it is diagnostics and devices too. Now we are not saying this to say less risk averse investors should move there because there is less risk there. To say there is less risk there is only partly right.

The regulatory and commercial pathways for devices and diagnostics are generally shorter, the capital requirements are lower, and the probability of reaching market is materially higher than for therapeutics. A diagnostic platform or imaging agent can often progress from concept to commercialisation in a fraction of the time required for a novel drug, and the clinical evidence burden tends to be narrower. That is why the sector has produced companies such as Telix, whose imaging portfolio has scaled rapidly across multiple jurisdictions.

However, “less risky” does not mean “low risk.” Devices and diagnostics face their own structural challenges, including reimbursement uncertainty, competitive commoditisation, and the need for sustained commercial execution. A diagnostic may clear regulatory hurdles but still struggle to secure payer coverage or clinician adoption. Devices can be displaced by incremental innovation from larger incumbents. The risk is different in character rather than lower in absolute terms.

The distinction that matters for investors is the nature of the binary event. Drug development concentrates risk in a small number of pivotal trials where failure can erase years of investment, as Opthea and Immutep demonstrated. Devices and diagnostics distribute risk across regulatory clearance, reimbursement, salesforce effectiveness and market penetration. The probability of catastrophic failure is lower, but the probability of commercial underperformance is higher. Investors often underestimate that second category.

The Investor’s Responsibility

The lesson from this period is not that the ASX biotech space has become more dangerous. It is that the sector has always required a particular kind of discipline. Investors need a working understanding of clinical trial design, realistic expectations of failure probabilities, position sizing that reflects binary outcomes and the patience to hold through volatility.

The ASX is home to genuine world‑class biotech innovation. The failures are real and frequent, but so are the successes. The sector does not ask investors to be fearless; it asks them to be honest about the odds. Those who are tend to build portfolios that survive the inevitable storms.